Methods and reagents for the treatment of immunoinflammatory disorders

A drug and inflammatory technology, applied in the field of treatment of immune inflammatory diseases and drug testing, can solve problems such as adverse side effects and effect changes

Inactive Publication Date: 2007-06-13
COMBINATORX
View PDF251 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The effects of these drugs may vary and their use is often associated with adverse side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and reagents for the treatment of immunoinflammatory disorders
  • Methods and reagents for the treatment of immunoinflammatory disorders
  • Methods and reagents for the treatment of immunoinflammatory disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0141] Example 1: Inhibition of parallel signaling pathways by amoxapine and paroxetine

[0142] Materials and methods

[0143] drug

[0144] Stock solutions of all drugs were prepared in DMSO except amoxapine which was prepared in 0.1 mM MES (2-(N-morpholinoethanesulfonic acid) (Sigma) buffer. Myristic acid-phorbol-acetate (PMA) (100 μg / ml) stock solution and ionomycin (5 mg / ml) in DMSO were diluted in culture medium to produce final concentrations of PMA (10 ng / ml, 16.2 nM) and ionomycin ( 750 μg / ml, 1 μM).

[0145] Cells and Cell Lines

[0146] Fresh buffy coat preparations prepared from donated human whole blood (Red Cross, Rhode Island) were used to isolate peripheral blood mononuclear cells (PBMCs) by Ficoll-Plaque (Pharmacia) layered centrifugation. T cells were purified from PBMCs using "Pan T cell Isolation Kit II-human", (Miltenenyibiotec, Germany). The lymphoid leukemia T cell line (CCRF-CEM) was obtained from American Type Cell Culture (ATCC). All cells were ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention involves the treatment, prevention, and reduction of immunoinflammatory disorders involving the combination of an agent that increases the signal activity of a glucocorticoid receptor (e.g., glucocorticoid receptor agonist) and an agent that modulates the signaling activity of one or more signaling pathways selected from the NF-kappaB pathway, NFAT pathway, AP-1 pathway, and Elk-1 pathway such that proinflammatory cytokine secretion or production, or any other inflammatory response, is reduced. Further, screening methods are provided for identifying candidate compounds and strategies useful for treating, preventing, or reducing such conditions.

Description

field of invention [0001] In general, the present invention relates to the treatment, prevention and alleviation of immunoinflammatory diseases. Further, screening methods are provided for identifying candidate compounds and strategies for treating, preventing or alleviating these symptoms. Background of the invention [0002] The present invention relates to the treatment, prevention or alleviation of immunoinflammatory diseases. [0003] An immunoinflammatory disorder characterized by inappropriate activation of the body's immune defenses. The immune response is directed at and damages the body's own or transplanted tissue rather than the infectious invader. The tissues targeted by the immune system vary with disease. In multiple sclerosis, for example, the immune response is directed at neuronal tissue, while in Crohn's disease the digestive tract is the target. Immunoinflammatory diseases affect millions of individuals and include symptoms such as asthma, allergic in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/00A61K31/44A61K31/415A61K31/19A61K31/59A61K31/35A61K31/195A61K33/02A61K38/00A61K39/395A01N37/36A61K31/192A61K31/4745A61K31/522A61K38/13A61K45/06C07K16/18G01N33/74
CPCA61K31/59A61K31/192G01N2333/723A61K38/13G01N33/743A61K2039/505C07K16/18A61K31/4745C07K2316/96A61K45/06A61K31/522A61K31/415A61P29/00A61P37/00A61P43/00A61K2300/00
Inventor P·马尼瓦萨坎E·R·乔斯特-普赖斯J·斯陶恩顿C·凯思
Owner COMBINATORX
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap